| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 22.05.
| POZEN to Present at the Jefferies 2012 Global Healthcare Conference | | 27 | Business Wire |
| POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to
transforming medicine that transforms lives, announced today that John
R. Plachetka, Pharm.D., the Company's...
Mehr lesen zu:
POZEN to Present at the Jefferies 2012 Global Healthcare Conference | |
| 21.05.
| Post Earnings Update: Pozen Has Sunk 5.0% Lower in Past 2 Weeks | | 1 | SmarTrend |
| 21.05.
| POZEN (POZN) Says PA32540 Gets to Gastric pH Faster than Enteric-Coated Omeprazole | | 1 | StreetInsider.com |
| 14.05.
| Pozen Shares On The Rebound Since European Migraine Licensing Deal | | 1 | Seeking Alpha |
| 09.05.
| Pozen signs licensing deal with Desitin for MT 400 migraine therapy | | 2 | Pharma Bus Review |
| 08.05.
| POZEN (POZN) Enters MT 400 Licensing Deal with Desitin Arzneimittel | | - | StreetInsider.com |
| 08.05.
| POZEN Announces Licensing Deal with Desitin Arzneimittel GMBH for MT 400 Migraine Treatment in 29 European Countries | | 34 | Business Wire |
| POZEN Inc. (NASDAQ: POZN),
a pharmaceutical company
committed to transforming medicine that transforms lives, today
announced that it has entered into a license...
Mehr lesen zu:
POZEN Announces Licensing Deal with Desitin Arzneimittel GMBH for MT 400 Migraine Treatment in 29 European Countries | |
| 03.05.
| POZEN INC /NC - 10-Q, Quarterly Report | | - | SEC Filings |
| 01.05.
| UPDATE 1-Pozen posts wider loss, to review forecast | | 1 | Reuters.com |
| 01.05.
| POZEN Reports PA32540 / PA8140 Updates and First Quarter 2012 Financial Results | | 47 | Business Wire |
| POZEN Inc. (NASDAQ: POZN),
a pharmaceutical company
committed to transforming medicine that transforms lives, today
announced results for the first quarter ended...
Mehr lesen zu:
POZEN Reports PA32540 / PA8140 Updates and First Quarter 2012 Financial Results | |
| 30.04.
| Pozen Makes a Move: Up 4.8% | | - | SmarTrend |
| 18.04.
| POZEN Announces May 1, 2012 Webcast of First Quarter 2012 Results | | 37 | Business Wire |
| POZEN Inc. (NASDAQ: POZN),
a pharmaceutical company
committed to transforming medicine that transforms lives, announced
today that it plans to release first quarter...
Mehr lesen zu:
POZEN Announces May 1, 2012 Webcast of First Quarter 2012 Results | |
| 12.04.
| Watch for Continued Gains in Shares of Pozen | | 3 | SmarTrend |
| 10.04.
| Robert Pozen: An Intermediate Approach to the Auditor Rotation Issue | | 1 | Huffington Post |
| 05.04.
| 88.4% Return Seen to Date on SmarTrend Pozen Call | | 2 | SmarTrend |
| 02.04.
| Pozen Makes a Move: Up 5.8% | | - | SmarTrend |
| 02.04.
| Pozen Rising Today on Above-Average Volume | | - | SmarTrend |
| 29.03.
| Pozen is Among the Companies in the Pharmaceuticals Industry With the Highest Revenue Per Employee | | 2 | SmarTrend |
| 26.03.
| Pozen's CEO Responds to Questions About His Firm's Latest Developments and Positive Key Clinical Trial Results | | 33 | MarketWire |
| LOS ANGELES, CA -- (Marketwire) -- 03/26/12 -- Last week, shares of Pozen Inc. (NASDAQ: POZN) -- a developer of novel pharmacologic agents primarily for pain and pain-related conditions -- rose the...
Mehr lesen zu:
Pozen's CEO Responds to Questions About His Firm's Latest Developments and Positive Key Clinical Trial Results | |
| 22.03.
| POZEN's Safer Aspirin Meets Goals In Pivotal Studies | | 39 | AFX News |
| WASHINGTON (dpa-AFX) - POZEN Inc. (POZN) announced Thursday that its
investigational drug, PA32540, achieved its primary endpoint of a significant
reduction in the cumulative incidence of...
Mehr lesen zu:
POZEN's Safer Aspirin Meets Goals In Pivotal Studies | |
